Actively Recruiting
Pan-tumor MRD Study
Led by Paradigm Health · Updated on 2025-08-14
1350
Participants Needed
2
Research Sites
377 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
CONDITIONS
Official Title
Pan-tumor MRD Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed diagnosis of malignant solid tumor in specified cohorts or eligible for Mix of Solid Tumors cohort
- Eligible for curative intent therapy with planned surgical cancer resection
- Enrollment within 3 months after surgery and before starting additional therapy if surgery already done
- ECOG performance status of 0, 1, or 2
- No systemic therapy for current cancer before enrollment
- Willing and able to comply with study procedures including blood and tumor tissue collection
- Completed all therapy for any previous invasive solid organ or hematologic cancer 3 or more years ago, except nonmelanoma skin cancers
- No concurrent diagnosis of another invasive cancer except nonmelanoma skin cancers
- No prior allogeneic hematopoietic stem cell transplant
- Able and willing to provide informed consent and HIPAA authorization
- Muscle-invasive bladder cancer and melanoma cohorts: Stage II or operable stage III
- Esophageal, gastric/GEJ, and NSCLC cohorts: Stage I, II, or operable stage III
- Pancreatic cohort: Stage I, II, or operable stage III, exocrine only
- Mix of Solid Tumors cohort: Stage II or operable stage III meeting eligibility and not in other cohorts
You will not qualify if you...
- Central nervous system malignancies
- Colorectal cancer
- Breast cancer
- Squamous cell skin cancer
- Basal cell carcinoma
- Gastrointestinal stromal tumors (GIST)
- Thyroid cancer
- Uveal melanoma
- Low or intermediate grade neuroendocrine tumors except high-grade neuroendocrine tumors, neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer
- Hematologic cancers including multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia/small lymphocytic leukemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Medical Oncology Associates of San Diego
San Diego, California, United States, 92123
Actively Recruiting
2
Taylor Cancer Research Center
Maumee, Ohio, United States, 43437
Actively Recruiting
Research Team
A
Anosheh Afghahi, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here